The BCH blog Vector talks about the progress of rFIXFc, a recombinant hybrid of Factor IX and an Fc receptor fragment, a new long lasting clotting factor which recently passed a phase 3 clinical trial. The technology is the result of a collaboration Wayne Lencer, a researcher at Boston Children’s Hospital, Richard Blumberg from Brigham and Women’s Hospital (BWH) and Associate Professor of Biology Neil Simister from Brandeis. We’re all excited to see this technology emerge from the labs, and progress to the point where it’s poised to make a significant impact in the lives of hemophilia patients.
Driving into work this morning, I heard that Biogen Idec is seeking FDA approval for a new breakthrough drug to treat Hemophilia A. The drug, a recombinant factor VIII Fc fusion protein (rFVIIIFc), provides a longer-lasting version of the clotting factor that is missing in these patients, and could help significantly reduce the frequency of injections for these patients (a big deal for children with an inherited bleeding disorder!)
The fusion protein approach is based on technology developed in part at Brandeis, by a collaboration involving Neil Simister‘s laboratory and researchers at Children’s Hospital and Brigham and Women’s Hospital, then further developed by a spinoff company, Syntonix Pharmaceuticals. Syntonix was acquired by Biogen Idec in 2007.
BrandeisNOW has a new story about the development of recombinant Factor IX Fc, a candidate drug for hemophila, currently in Phase III cliniical trials. The story behind the Fc fusion technology started in academic labs including Neil Simister‘s at Brandeis, led to a biotech startup (Syntonix), which was then acquired by Biogen Idec, who are now conducing clinical trials.
For more, see http://www.brandeis.edu/now/2011/june/hemophilia.html